SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VPHM - Viropharma Inc -- Ignore unavailable to you. Want to Upgrade?

To: IRWIN JAMES FRANKEL who wrote (2542)5/1/2012 7:17:27 AM
From: IRWIN JAMES FRANKEL  Read Replies (1) | Respond to of 2557
 
Cum Cinryze $594.9M.

:-(

Well - by next Q it is a SLAM DUNK.

:-)

ij



To: IRWIN JAMES FRANKEL who wrote (2542)5/1/2012 8:22:48 AM
From: IRWIN JAMES FRANKEL  Respond to of 2557
 
>> Cost of sales increased over the three month period in the prior year by $13.2 million primarily due to increased Cinryze volume coupled with lower Vancocin volumes and a royalty payment due on Vancocin sales.

Anyone know how big that royalty payment is?

Just guessing but it looks like at least $5M just to get the relative COGS equations to a non-negative COGS on V.

:-)

ij


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News